Craneware (LON:CRW) Given Buy Rating at UBS Group

UBS Group reissued their buy rating on shares of Craneware (LON:CRW) in a report released on Wednesday morning, Marketbeat Ratings reports. They currently have a GBX 570 target price on the stock.

Several other equities analysts have also issued reports on the stock. Shore Capital Group reissued a “buy” rating and issued a GBX 2,850 price target on shares of Craneware in a report on Tuesday, January 20th. Berenberg Bank reiterated a “buy” rating and set a GBX 2,900 target price on shares of Craneware in a report on Tuesday, January 20th. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of GBX 2,297.75.

Craneware Trading Down 0.4%

CRW opened at GBX 1,330 on Wednesday. The firm’s fifty day moving average is GBX 1,548.14 and its two-hundred day moving average is GBX 1,941.07. The company has a debt-to-equity ratio of 7.93, a quick ratio of 1.00 and a current ratio of 0.76. The firm has a market cap of £472.27 million, a PE ratio of 24.09 and a beta of 0.28. Craneware has a twelve month low of GBX 1,290 and a twelve month high of GBX 2,644.

Craneware Company Profile

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in healthcare financial and operational transformation, delivering cutting-edge technologies that drive measurable impact. Our Trisus® cloud ecosystem unifies data, revenue intelligence, margin intelligence, and advanced analytics, enabling healthcare organizations to optimize performance, improve financial sustainability, and drive strategic growth. As a trusted Microsoft partner, we provide future-ready solutions-including the Best in KLAS Trisus Chargemaster – that simplify the complexities of healthcare finance and operations.